Deerfield Management Company, L.P. (Series C) Taysha Gene Therapies, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2021 May 17, 2021	SELL	$20.3 - $31.75 $5.08 Million - $7.94 Million	-250,000 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$22.4 - $24.47 $5.6 Million - $6.12 Million	250,000 New	250,000 $5.6 Million

Others Institutions Holding TSHA

# of Institutions

117

Shares Held

136M

Call Options Held

25.9K

Put Options Held

24K

Avoro Capital Advisors LLC New York, NY

18.7M
Shares

$32.8 Million
0.56% of portfolio
Rtw Investments, LP New York, NY

14.9M
Shares

$26.3 Million
0.48% of portfolio
Black Rock Inc. New York, NY

11.7M
Shares

$20.7 Million
0.0% of portfolio
Ra Capital Management, L.P. Boston, MA

10.9M
Shares

$19.1 Million
0.3% of portfolio
Vr Adviser, LLC New York, NY

9M
Shares

$15.8 Million
1.87% of portfolio

View Full List

About Taysha Gene Therapies, Inc.

Ticker TSHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,359,500
Market Cap $85.1M
Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...

More about TSHA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account